Primary Results From APOLLO-B Open-label Extension Study Of Patisiran In Patients With Transthyretin Cardiac Amyloidosis

The Phase 3, placebo-controlled APOLLO-B study (NCT03997383) is evaluating the efficacy and safety of patisiran in patients (pts) with ATTR cardiac amyloidosis in a 12-month (M) double-blind (DB) period followed by an open-label extension (OLE) period when all pts receive patisiran. During the DB period, patisiran demonstrated statistically significant differences vs placebo in change from baseline (CFB) to M12 in 6-minute walk test (6MWT) and KCCQ-OS, and nominal significance in NT-proBNP and troponin I.

Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Mathew S. Maurer, John L. Berk, Mazen A. Hanna, Julian D. Gillmore, Pedro V. Schwartzmann, Olivier Lairez, Masaru Hatano, Hyun-Jai Cho, Peter van der Meer, Matthew T. White, Elena Yureneva, Marianne T. Sweetser, Patrick Y. Jay, John Vest, Marianna Fontana Tags: 021 Source Type: research